{"name": "Alexion Pharmaceuticals",
 "permalink": "alexion-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/alexion-pharmaceuticals",
 "homepage_url": "http://www.alexionpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "203-272-2596",
 "description": "",
 "created_at": "Tue Feb 01 04:59:26 UTC 2011",
 "updated_at": "Fri Jun 03 04:47:00 UTC 2011",
 "overview": "\u003Cp\u003EAlexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. for the production of Soliris. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       33],
      "assets/images/resized/0011/9814/119814v1-max-150x150.png"],
     [[216,
       48],
      "assets/images/resized/0011/9814/119814v1-max-250x250.png"],
     [[216,
       48],
      "assets/images/resized/0011/9814/119814v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Leonard",
      "last_name": "Bell",
      "permalink": "leonard-bell",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Vikas",
      "last_name": "Sinha",
      "permalink": "vikas-sinha",
      "image": null}},
   {"is_past": true,
    "title": "SVP, Translational Medicine",
    "person":
     {"first_name": "Abbie",
      "last_name": "Celniker",
      "permalink": "abbie-celniker",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7349/267349v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7349/267349v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7349/267349v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 111000000.0,
    "price_currency_code": "USD",
    "term_code": "cash",
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily2-Taligen-Therapeutics-acquired-for-111M.html",
    "source_description": "Taligen Therapeutics acquired for $111M",
    "acquired_year": 2011,
    "acquired_month": 1,
    "acquired_day": 31,
    "company":
     {"name": "Taligen Therapeutics",
      "permalink": "taligen-therapeutics",
      "image":
       {"available_sizes":
         [[[150,
            61],
           "assets/images/resized/0005/0041/50041v2-max-150x150.jpg"],
          [[250,
            102],
           "assets/images/resized/0005/0041/50041v2-max-250x250.jpg"],
          [[350,
            144],
           "assets/images/resized/0005/0041/50041v2-max-450x450.jpg"]],
        "attribution": null}}},
   {"price_amount": null,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://finance.yahoo.com/news/Alexion-Pharmaceuticals-wscheats-97749478.html?x=0",
    "source_description": "Alexion Pharmaceuticals to Acquire Enobia Pharma Corp.",
    "acquired_year": 2011,
    "acquired_month": 12,
    "acquired_day": 29,
    "company":
     {"name": "Enobia Pharma",
      "permalink": "enobia-pharma",
      "image":
       {"available_sizes":
         [[[150,
            145],
           "assets/images/resized/0006/0774/60774v1-max-150x150.png"],
          [[153,
            148],
           "assets/images/resized/0006/0774/60774v1-max-250x250.png"],
          [[153,
            148],
           "assets/images/resized/0006/0774/60774v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "352 Knotter Drive",
    "address2": "",
    "zip_code": "06410",
    "city": "Cheshire",
    "state_code": "CT",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "acquired patents and assets for a possible therapy for a ultra-rare genetic disorder for $3 million in cash from Germany-based Orphatec Pharmaceuticals GmbH",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 10,
    "source_url": "http://www.masshightech.com/stories/2011/02/07/daily45-Alexion-buys-IP-from-German-biotech-for-infant-disorder.html",
    "source_text": null,
    "source_description": "Alexion buys IP from German biotech for infant disorder",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alexion Pharmaceuticals",
      "permalink": "alexion-pharmaceuticals"}},
   {"description": "has won approval from its board of directors for a two-for-one stock split, which if approved would double the number of issued common stock shares from 145 million to 290 million",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 30,
    "source_url": "http://www.masshightech.com/stories/2011/03/28/daily27-Alexion-gets-board-OK-for-stock-2-1-split.html",
    "source_text": null,
    "source_description": "Alexion gets board OK for stock 2-1 split",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alexion Pharmaceuticals",
      "permalink": "alexion-pharmaceuticals"}},
   {"description": "has won priority review from the U.S. Food and Drug Administration",
    "stoned_year": 2011,
    "stoned_month": 6,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/05/30/daily25-Alexion-lands-FDA-priority-review-for-blood-clotting-drug-target.html",
    "source_text": null,
    "source_description": "Alexion lands FDA priority review for blood clotting drug target",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alexion Pharmaceuticals",
      "permalink": "alexion-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ALXN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}